10x Genomics/$TXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Ticker
$TXG
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
1,306
ISIN
US88025U1097
Website
10x Genomics Metrics
BasicAdvanced
$1.4B
-
-$1.30
1.94
-
Price and volume
Market cap
$1.4B
Beta
1.94
52-week high
$23.67
52-week low
$6.78
Average daily volume
4.2M
Financial strength
Current ratio
5.373
Quick ratio
4.444
Long term debt to equity
9.992
Total debt to equity
11.328
Interest coverage (TTM)
-59,829.67%
Profitability
EBITDA (TTM)
-146.882
Gross margin (TTM)
68.36%
Net profit margin (TTM)
-25.14%
Operating margin (TTM)
-28.73%
Effective tax rate (TTM)
-2.37%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-12.43%
Return on equity (TTM)
-22.03%
Valuation
Price to revenue (TTM)
2.277
Price to book
2.04
Price to tangible book (TTM)
2.1
Price to free cash flow (TTM)
32.06
Free cash flow yield (TTM)
3.12%
Free cash flow per share (TTM)
36.59%
Growth
Revenue change (TTM)
-0.13%
Earnings per share change (TTM)
-42.13%
3-year revenue growth (CAGR)
7.76%
3-year earnings per share growth (CAGR)
17.44%
What the Analysts think about 10x Genomics
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
Bulls say / Bears say
10x Genomics' strong portfolio of intellectual property and the widespread recognition of its products demonstrate its commitment to innovation, positioning the company favorably in the genomics market. (Insider Monkey)
The company's recent launch of GEM-X technology enables higher performance at larger scale and lower cost, potentially driving increased adoption and revenue growth. (Life Science Report)
Analysts maintain an optimistic outlook on 10x Genomics, with an 'Overweight' rating and a price target of $24.00, indicating confidence in the company's ability to navigate current challenges and capitalize on future growth opportunities. (Investing.com)
Prolonged weakness in genomics capital expenditure could significantly hamper 10x Genomics' growth trajectory, as the company's revenue is heavily dependent on instrument sales, particularly for its Xenium platform. (Investing.com)
The ongoing difficulties with the Xenium instrumentation line pose a significant risk to 10x Genomics' growth prospects, potentially leading to continued underperformance and negatively impacting investor confidence. (Investing.com)
The current challenging macroeconomic climate presents a significant threat to 10x Genomics' business model, as research institutions and pharmaceutical companies may face budget constraints, leading to delayed or canceled purchases of genomic equipment and consumables. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
10x Genomics Financial Performance
Revenues and expenses
10x Genomics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 10x Genomics stock?
10x Genomics (TXG) has a market cap of $1.4B as of June 30, 2025.
What is the P/E ratio for 10x Genomics stock?
The price to earnings (P/E) ratio for 10x Genomics (TXG) stock is 0 as of June 30, 2025.
Does 10x Genomics stock pay dividends?
No, 10x Genomics (TXG) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next 10x Genomics dividend payment date?
10x Genomics (TXG) stock does not pay dividends to its shareholders.
What is the beta indicator for 10x Genomics?
10x Genomics (TXG) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.